• Home
  • Argent BioPharma ltd

Argent BioPharma ltd

  • Argent BioPharma Slovenia Head office
About Argent BioPharma ltd

Argent BioPharma, an innovative drug discovery company listed on the London Stock Exchange, is enhancing its commitment to accessible medical treatments with advancements in poly pharmacology and nanotechnology.
As a clinical-stage, revenue-generating biopharmaceutical company, we focus on addressing unmet medical needs through cutting-edge research and development.

At Argent Biopharma, we provide comprehensive Contract Manufacturing Organization (CMO) services for non-sterile oral liquid dosage forms. With a GMP certified facility and fully automated production.

Read more Show less
Certifications
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • GB
  • 2024
    On CPHI since
  • 1
    Certificates
  • 50 - 99
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile
Contact info
Show contact info Hide contact info

Products from Argent BioPharma ltd (7)

  • CimetrA®

    Product CimetrA®

    Early Stage Revenue Generating Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date. Results of Preclinical and Clinical program, meeting FDA guidelines, to date: • Demon...
  • IrniCann®

    Product IrniCann®

    Pre-Clinical Stage Glioblastoma • Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease​ • An estimated 250,000 new cases of GBM per year worldwide....
  • CannEpil

    Product CannEpil

    CannEpil®, one of Argent BioPharma's flagship products, is an enhanced iteration of a compounded isolated cannabinoid formulation. It leverages well-known historical data to become one of the first compounded prescription investigational drugs used for seizure management over the past years. The active ing...
  • CimetrA

    Product CimetrA

    Early Stage Revenue Generating Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date.
    Results of Preclinical and Clinical program, meeting FDA guide...
  • CogniCann

    Product CogniCann

    CogniCann® is an Investigational Medicinal Product based on two APIs, low CBD and high THC, designed to be used for symptoms associated with Dementia and Alzheimer's.

    A Phase II, randomized, double-blind cross-over, placebo-controlled clinical study designed to evaluate the clinical efficacy of ...
  • DerNaPol

    Product DerNaPol

    Chronic wounds are a major global health issue, costing billions in treatment annually (e.g., £3.2 billion in the UK 1in 2015; $28.1 to $96.8 billion in the USA in 20142). These wounds cause extreme sufferingwith severe symptoms, often complicated by antibiotic-resistant infections,impenetrablebiofilmsand ...
  • IrniCann

    Product IrniCann

    Pre-Clinical Stage Glioblastoma • Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease​• An estimated 250,000 new cases of GBM per year...

Argent BioPharma ltd Resources (1)